Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
Article Date
June 20, 2023
This article is featured on another website.
Go to article
January 26, 2026
Leveraging China to Maximize Global Study Impact
China's healthcare market is expanding rapidly due to urbanization, with a population of about 1.4…
January 26, 2026
Leveraging China to Maximize Global Study Impact
China's healthcare market is expanding rapidly due to urbanization, with a population of about 1.4…